Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Franz J. Zemp"'
Autor:
Runze Yang, Jeff Dunn, John Kelly, Reza Mirzaei, Candice Poon, Pinaki Bose, Susobhan Sarkar, Manoj Kumar Mishra, Khalil S. Rawji, Franz J. Zemp, V. Wee Yong
Publikováno v:
Science translational medicine. 12(537)
Glioblastomas are generally incurable partly because monocytes, macrophages, and microglia in afflicted patients do not function in an antitumor capacity. Medications that reactivate these macrophages/microglia, as well as circulating monocytes that
Autor:
Robin M. Yates, Bas G.J. Surewaard, John Conly, Abdelwahab Omri, Matthias Amrein, Michael Otto, Justin F. Deniset, Paul Kubes, Franz J. Zemp
Publikováno v:
The Journal of Experimental Medicine
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is reaching epidemic proportions causing morbidity, mortality, and chronic disease due to relapses, suggesting an intracellular reservoir. Using spinning-disk confocal intravital microscop
Autor:
John Kelly, Franz J. Zemp, Donna L. Senger, J. Gregory Cairncross, Beichen Sun, Mohamed R. Mohamed, Brian Rabinovich, John C. Bell, Brienne A. McKenzie, Sherin Smallwood, Peter A. Forsyth, Mark G. Hamilton, Samuel Weiss, Lori Maxwell, Masmudur M. Rahman, Xueqing Lun, Hongyuan Zhou, Grant McFadden, Artee Luchman, Owen Stechishin
Publikováno v:
Neuro-Oncology. 15:904-920
Background. Intratumoral heterogeneity in glioblastoma multiforme (GBM) poses a significant barrier to therapy in certain subpopulation such as the tumorinitiating cell population, being shown to be refractory to conventional therapies. Oncolytic vir
Autor:
Franz J. Zemp, Alexandra Pisklakova, Rajappa S. Kenchappa, Brienne A. McKenzie, Grant McFadden, Peter A. Forsyth
BACKGROUND: GBM is a deadly brain cancer with an average survival of 12 months. In the past, a treatment-resistant Brain Tumor Initiating Cell (BTIC) compartment has been identified and is thought to drive tumor recurrence. One experimental strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c50eadf430cf0f33c024002c248dd6f1
https://europepmc.org/articles/PMC4638488/
https://europepmc.org/articles/PMC4638488/
Autor:
Franz J. Zemp, Rajappa S. Kenchappa, Peter A. Forsyth, Brienne A. McKenzie, Aru Narendran, Ebba U Kurz, Xueqing Lun, Grant McFadden, Alexandra Pisklakova
Brain tumor-initiating cells (BTICs) are stem-like cells hypothesized to form a disease reservoir that mediates tumor recurrence in high-grade gliomas. Oncolytic virotherapy uses replication-competent viruses to target and kill malignant cells and ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f090a556dc4fed6132bd78ec7d64b0d
https://europepmc.org/articles/PMC4490869/
https://europepmc.org/articles/PMC4490869/
Autor:
Brienne A. McKenzie, Franz J. Zemp, Lori Maxwell, V. Wee Yong, Grant McFadden, Xueqing Lun, Karlyne M. Reilly, Peter A. Forsyth
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 6, p e65801 (2013)
PLoS ONE, Vol 8, Iss 6, p e65801 (2013)
Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumou
Autor:
Mauro Costa-Mattioli, Sara C. Kozma, George Thomas, Dominic G. Roy, Tommy Alain, John C. Bell, Xueqing Lun, Peter A. Forsyth, Bali Pulendran, Nahum Sonenberg, Polen Sean, Chantal G Lemay, Emmanuel Petroulakis, Yvan Martineau, Franz J. Zemp
Oncolytic viruses constitute a promising therapy against malignant gliomas (MGs). However, virus-induced type I IFN greatly limits its clinical application. The kinase mammalian target of rapamycin (mTOR) stimulates type I IFN production via phosphor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b13a52b2547297cad73a392b9fff24
https://europepmc.org/articles/PMC2824402/
https://europepmc.org/articles/PMC2824402/
Autor:
John C. Bell, Dominic G. Roy, Polen Sean, Tommy Alain, Emmanuel Petroulakis, Bali Pulendran, Yvan Martineau, Nahum Sonenberg, Chantal G Lemay, Franz J. Zemp, George Thomas, Sara C. Kozma, Xueqing Lun, Peter A. Forsyth, Mauro Costa-Mattioli
Publikováno v:
Cancer Research. 70:5349-5349
Oncolytic viruses constitute a promising therapy against malignant gliomas (MGs). However, virus-induced type-I interferon (IFN) greatly limits its clinical application. The kinase mTOR (mammalian target of rapamycin) stimulates type-I IFN production